
Sanofi’s investigational multiple sclerosis drug Lemtrada has beaten Rebif in a late-stage trial. The Phase III results show that 78% …

Genzyme’s multiple sclerosis candidate Lemtrada has impressed in a new phase II head-to-head trial. Five years’ worth of mid-stage data …

Sanofi-Aventis has entered into a confidentiality agreement with Genzyme to discuss the prospects of Lemtrada, which suggests a deal could …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

